At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIOR Biora Therapeutics, Inc.
Closed Good Friday 04-17 16:00:00 EDT Delay
Biora Therapeutics Files for Chapter 11, Secures $10.25 Million Financing for Sale Process
MT Newswires Live · 2024-12-30
Biora Therapeutics Files for Chapter 11 Bankruptcy
Dow Jones · 2024-12-30
Biora Therapeutics Inc - Secures up to $10.25 Million in Debtor in Possession Financing
THOMSON REUTERS · 2024-12-30
Biora Therapeutics Inc - to File Motion for Approval of Marketing and Sale Process
THOMSON REUTERS · 2024-12-30
Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
THOMSON REUTERS · 2024-12-30
Press Release: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth
Dow Jones · 2024-12-30
Biora Therapeutics Files for Chapter 11 Bankruptcy - Court Filing
THOMSON REUTERS · 2024-12-28
Biora Therapeutics Lists Estimated Assets Between $10 Mln to $50 Mln and Estimated Liabilities Between $100 Mln and $500 Mln - Court Filing
THOMSON REUTERS · 2024-12-28
Top Midday Decliners
MT Newswires Live · 2024-12-10
Dow Falls 150 Points; Oracle Posts Downbeat Results
Benzinga · 2024-12-10
Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket
MT Newswires Live · 2024-12-10
Biora Therapeutics Inc - Nasdaq to Delist Biora Therapeutics Due to Non-Compliance
THOMSON REUTERS · 2024-12-10
Biora Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2024-11-18
Biora Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 2024-11-15
Highbridge Capital Management, Llc Reports 9.99% Passive Stake in Biora Therapeutics Inc as of Sept 30, 2024- SEC Filing
THOMSON REUTERS · 2024-11-14
BRIEF-Biora Therapeutics Provides Corporate Update And Reports Third Quarter 2024 Financial Results
Reuters · 2024-11-14
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
THOMSON REUTERS · 2024-11-14
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Reuters · 2024-11-13
Biora Therapeutics Inc expected to post a loss of $3.85 a share - Earnings Preview
Reuters · 2024-11-08
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
THOMSON REUTERS · 2024-11-07
Introduction
Company Name.
Biora Therapeutics, Inc.
Affiliated Markets:
PINK
Listing Date:
2020-06-19
Main Business:
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Issue price:
15.00
Invest in Global Markets with Tiger Brokers!Open App